Drugs

FDA Plans National DTC Advertising Survey

FDA has announced a planned “National Direct-to-Consumer (DTC) Advertising Survey” to obtain updated insights on consumer experiences with and attitudes towards DTC prescription drug promotion. The agency last surveyed patients about their experiences with and attitudes toward DTC advertising in 2002, according to a notice seeking comments on the survey. “Numerous changes have affected the DTC landscape since 2002, including declines in print readership, the rise in online prescription drug promotion, and self-imposed industry guidelines for DTC advertising,” it says. “These changes may have affected consumers’ exposure to different kinds of DTC advertising and its influence on their attitudes and behaviors.”

Mailed survey invitations will ask 5,000 consumers to complete an online 20-minute questionnaire about their knowledge of FDA's authority with respect to prescription drug advertising, exposure to DTC advertising, beliefs and attitudes about DTC advertising, and the influence of DTC advertising on further information search and patient-physician interactions, according to the notice. The agency estimates a 35% response rate with 1,700 expected to complete the survey.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome